Featured Story | By Ben Adams With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year, and switching focus to its second mRNA asset with GlaxoSmithKline. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Johnson & Johnson Chief Scientific Officer Paul Stoffels is to retire at the end of the year, ending a nine-year stint at the top of the rejuvenated R&D unit and creating more turnover at the top of the Big Pharma. read more By Kyle LaHucik Last week it was Selecta Biosciences. This week, Takeda's gene therapy investment push is helping lift Poseida in a potentially $3.6 billion research collaboration and licensing deal that will give the Japanese Big Pharma access to up to eight non-viral gene therapies for liver and hematologic diseases. read more Sponsored by: Thermo Fisher Scientific Discover ways your Thermo Scientific™ KingFisher™ system can empower your research beyond SARS-CoV-2. read more By Nick Paul Taylor Dana-Farber Cancer Institute has reportedly barred trustees from newly investing in biotechs created to license its science, leading to the resignation of board members including a co-founder of C4 Therapeutics. read more Sponsored by: Syntropy Q&A with Syntropy and UCI on their collaboration to work across their enterprise and with external partners to advance health research and patient care. read more By Annalee Armstrong Almost a year to the day after Gossamer Bio’s lead program failed twice in phase 2, the California biotech is unveiling two preclinical assets ready to enter the clinic in an effort to turn things around. read more By Annalee Armstrong Roche’s Spark Therapeutics unit is offering up to $328.5 million in biobucks for CombiGene’s gene therapy for epilepsy, which has a specific focus on drug-resistant forms of the condition. read more By Conor Hale The company also delivered recent findings that showed the Percepta genomic test’s ability to more accurately separate groups of patients based on their risk of developing tumors from suspicious lung nodules. read more By Angus Liu Patients with itchy eyes caused by allergic inflammation often take eye drops multiple times per day. Thanks to an FDA approval, a monthly insert into the canaliculus of the eye will soon be available. read more By Robert King A new poll finds that a large swath of the public aren't buying the pharmaceutical industry's arguments against giving Medicare drug price negotiation authority. read more Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored By: Trial Interactive Check out the eTMF Implementation Quick Guide to see a checklist TMF experts developed to help you reduce risks, maintain compliance, and establish effective processes in your eTMF. Sponsored By: Bioclinica This whitepaper addresses where AI can make the biggest impact in clinical trials. Sponsored by: Thermo Fisher Scientific Looking to accelerate your biotech company, but not sure where to start? Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: LabVantage Solutions Shift from data collection to data science. Add advanced analytics to your lab informatics platform to yield valuable, action-ready insights from LIMS and other data. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Thermo Fisher Scientific Integrate supply chain simulation into your early clinical trial planning to minimize risk in an uncertain supply chain environment, improve supply chain outcomes, and help streamline time-to-market for innovative therapies. Sponsored by: WCG Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
.png)
